RAIDEN RESOURCES LIMITED — Interim / Quarterly Report 2005

Jan 30, 2006

Notes for the Appendix 4C Quarterly Cash Statement for 31 December 2005

MEDICAL MONITORS LIMITED (the "Company") ASX: MDM / MDMDA

During the past quarter, the Company received further part payments in sales revenue for newly manufactured devices delivered to the USA-based monitoring service, iCardia Healthcare Corporation (iCardia), as had been anticipated.

However, on the expense side, a number of one-off payments also occurred during the quarter that included the Annual Report and Audit and manufacturing costs. These additional expenses were in line with expectations.

Subsequent events for January 2006, will show an inflow of funds of more than $250,000, as well as an R&D cash credit of $234,000 being received through the Ausindustry grants program. In addition, repayment of loan monies of more than $500,000, that has accrued over the past year, is expected from the company's overseas business ventures over the coming quarter.

As previously announced, the Directors of Primedical International, the distributor of the suPER™ ECG monitoring units in the USA, are pleased with the growing success of the iCardia monitoring service in Chicago, with more than 5,000 units having been activated for the monitoring of cardiac patients. A US national sales and marketing campaign is now well underway for 2006, utilising the recently delivered 15,000 suPER™ ECG monitoring units.

The Directors believe that sufficient funds, and other financial arrangements, are in place to provide for the payment of accounts as and when they fall due. The Directors further believe that there is a sound financial base for the Company to continue with its current programs, in Australia and overseas, and that the Company will benefit from the increasing sales revenue anticipated over the coming months.

The Directors are confident of the continuing success for the Company's products and services in Australia and internationally, and will keep the market informed of any new developments.

Dr Allan Shell Managing Director

Medical Monitors Limited Suite 407 Office Tower Westfield Eastgardens Eastgardens NSW 2036 Australia Tel 02 9344 8100 Fax 02 9344 8200 www.medmon.com.au

Rule 4.7B

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced31/3/2000.Amended30/9/2001

Name of entity

Medical Monitors Limited

ABN

68 009 161 522

Current quarter to

31 December 2005

Consolidated statement of monthly cash flow

Cash flows related to operating activities		Current Quarter$A'000	Year to date$(6$ months)
			SA'000
1.1	Receipts from customers	283	562
1.2	Payments for(a) staff costs(b) advertising and marketing(c) research and development(d) leased assets	(93)	(193)
1.3	(e) other working capitalDividends received	(310)	(815)
1.4	Interest and other items of a similar naturereceived
1.5	Interest and other costs of finance paid
1.6	Income taxes paid
1.7	Other (Govt Grants)	14	14
	Other (GST Refund)	27	67
	Other (Insurance Refund)
	Net operating cash flows	(79)	(365)

+ See chapter 19 for defined terms.

	Year to dateCurrent Quarter
		$A'000	$(6$ months)$A'000
1.8	Net operating eash flows (carried forward)	(79)	(365)
1.9	Cash flows related to investing activitiesPayment for acquisition of:
	(a) businesses (item 5)
	(b) equity investments(c) intellectual
	property
	(d) physicalnon-
	currentassets(e) other non-current
	assets
1.10	Proceeds from disposal of:(a) businesses (item 5)
	(b)equity investments
	(c) intellectualproperty
	(d) physicalnon-
	currentassets(e) other non-current
	assets
1.11	Loans to other entities	(286)	(513)
1.12	Loans repaid by other entities		110
1.13	Other (provide details if material)
	Net investing cash flows	(286)	(403)
1.14	Total operating and investing cash flows	(365)	(768)
	Cash flows related to financing activities
1.15	Proceeds from issues of shares, options, etc.		250
1.16	Proceeds from sale of forfeited shares
1.171.18	Proceeds from borrowingsRepayment of borrowings	160	340
1.19	Dividends paid
1.20	Other (Security Deposit)	160	590
	Net financing cash flows
	Net increase (decrease) in cash held	(205)	(178)
1.21	Cash at beginning of quarter/year to date	230	203
1.22	Exchange rate adjustments to item 1.20
1.23	Cash at end of quarter/month	25	25

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors Payments to related entities of the entity and associates of the related entities

		Current Quarter$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	12
1.25	Aggregate amount of loans to the parties included in item 1.11
1.26	Explanation necessary for an understanding of the transactions

Consultancy fees paid to research entities controlled by directors.

Non-cash financing and investing activities

• $2.1$ Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows
• $2.2$ Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

Financingfacilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available$A'000	Amountused$A'000
3.1	Loan facilities
3.2	Credit standby arrangements	.000	. .nıl

+ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of eash at the end of the quarter (asshown in the consolidated statement of cash flows) tothe related items in the accounts is as follows.		Current Quarter$A'000	Previous Quarter$A'000
4.1	Cash on hand and at bank	25	230
4.2	Deposits at call
4.3	Bank overdraft
44	Other (provide details)
	Total: cash at end of quarter $(i$ tem $1.22)$	25	230

Acquisitions and disposals of business entities

		Acquisitions(Item 1.9(a))	Disposals(Item 1.10(a))
5.1	Name of entity
5.2	Place of incorporationor registration
53	Consideration foracquisition or disposal
5.4	Total net assets
5.5	Nature of business

Compliance statement

• $\mathbf{1}$ This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
• $\overline{2}$ This statement does give a true and fair view of the matters disclosed.

(Director)

Date: 29th January 2006

Sign here:

Print name: Dr Allan Shell

+ See chapter 19 for defined terms.

Notes

• $11$ The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
• $2.$ The definitions in, and provisions of, AASB 1026: Statement of Cash Flows apply to this report except for the paragraphs of the Standard set out below.
  • $\bullet$ 6.2 - reconciliation of cash flows arising from operating activities to operating profit or loss
  • $9.2$ - itemised disclosure relating to acquisitions
  • 9.4 - itemised disclosure relating to disposals
  • $12.1(a)$ policy for classification of cash items
  • disclosure of restrictions on use of cash $12.3$
  • $13.1$ - comparative information
• $\overline{3}$ . Accounting Standards. ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

$+$ See chapter 19 for defined terms.